Novartis to acquire Myricx Bio in up to $1.5bn deal
The deal includes an upfront payment of $1.1bn and up to $400m in potential milestone payments. It is expected to close in the second half of 2026, pending
Japan-based Ono Pharmaceutical has signed an agreement with US biotechnology company Aitia to collaborate on drug discovery in neurological diseases.